Table 3.
Risk of major bleeding, all-cause mortality, and stroke/non-CNS SE/MI
| Variablea | Number of events | Proportion (%) | Univariable analysis | Multivariable analysisb | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |||
| Major bleeding | ||||||||
| Underweight | 9/542 | 1.66 | 1.15 | (0.57–2.30) | 0.692 | 0.97 | (0.48–1.98) | 0.939 |
| Normal | 70/4,410 | 1.59 | 1.00 | Reference | 1.00 | Reference | ||
| Overweight | 32/2,167 | 1.48 | 0.92 | (0.61–1.40) | 0.700 | 0.97 | (0.63–1.50) | 0.906 |
| Obese | 7/499 | 1.40 | 0.88 | (0.40–1.91) | 0.740 | 0.89 | (0.40–1.97) | 0.772 |
| All-cause mortality | ||||||||
| Underweight | 44/542 | 8.12 | 5.51 | (3.78–8.01) | < 0.001 | 3.56 | (2.40–5.26) | < 0.001 |
| Normal | 72/4,410 | 1.63 | 1.00 | Reference | 1.00 | Reference | ||
| Overweight | 33/2,167 | 1.52 | 0.92 | (0.61–1.39) | 0.705 | 1.19 | (0.77–1.83) | 0.427 |
| Obese | 4/499 | 0.80 | 0.49 | (0.18–1.33) | 0.161 | 0.74 | (0.27–2.05) | 0.562 |
| Stroke/non-CNS SE/MI | ||||||||
| Underweight | 15/540 | 2.78 | 2.11 | (1.20–3.70) | 0.009 | 1.64 | (0.90–2.99) | 0.104 |
| Normal | 63/4,392 | 1.43 | 1.00 | Reference | 1.00 | Reference | ||
| Overweight | 33/2,161 | 1.53 | 1.06 | (0.69–1.61) | 0.800 | 1.19 | (0.76–1.84) | 0.447 |
| Obese | 7/497 | 1.41 | 0.97 | (0.44–2.12) | 0.940 | 1.15 | (0.52–2.57) | 0.727 |
BMI body mass index, CHF congestive heart failure, CI confidence interval, CNS central nervous system, CrCl creatinine clearance, HR hazard ratio, MI myocardial infarction, SE systemic embolism, TIA transient ischemic attack
aBMI categories (kg/m2): underweight, < 18.5; normal, 18.5 to < 25; overweight, 25 to < 30; and obese, ≥ 30
bAdjusted for age (≥ 75/ < 75 years), sex (female/male), CrCl (< 50/ ≥ 50 ml/min), initial dose (10 mg/15 mg), hypertension (yes/no), diabetes mellitus (yes/no), CHF (yes/no), prior ischemic stroke/TIA (yes/no), vascular disease (yes/no), hepatic dysfunction (yes/no), and oral antiplatelet use (yes/no)